Healthcare Industry News: bone graft
News Release - September 24, 2008
Integra LifeSciences Announces Contract With NovationPLAINSBORO, N.J., Sept. 24, 2008 -- (Healthcare Sales & Marketing Network) -- Integra LifeSciences Holding Corporation (NasdaqGS:IART ) announced today that Integra OrthoBiologics has signed a three-year contract with Novation, one of the industry's leading contracting services companies, to supply Integra Mozaik(TM) Osteoconductive Scaffold, a novel collagen ceramic bone graft substitute product, to members of VHA, UHC and Provista. Integra OrthoBiologics is a world leader in high quality synthetic and human-derived bone graft material for use in both traditional and minimally invasive surgery, and was chosen for the quality, purity and value of its Integra Mozaik(TM) offering, and its outstanding customer service.
``We are extremely pleased that Novation has selected Integra as a contracted supplier of synthetic bone graft substitute,'' said Brian Larkin, President, Integra NeuroSciences. ``This new contract will allow us to build a long-term relationship with Novation and reflects its confidence in our commitment to providing VHA, UHC and Provista members with the highest quality products and service.''
Integra's OrthoBiologics products are used in several surgical disciplines (including orthopedics and spinal surgery) at more than 5,200 hospitals and surgery centers worldwide. They are sold through a distributor network consisting of 45 independent distributors with over 300 sales representatives. The Integra OrthoBiologics distributor network is provided additional marketing support by a direct sales team of 22 sales professionals.
About Integra LifeSciences Holdings Corporation
Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of cost-effective surgical implants and medical instruments. Integra's products, used primarily in neurosurgery, extremity reconstruction, orthopedics and general surgery, are used to treat millions of patients every year. The company's headquarters are in Plainsboro, New Jersey, and it has research and manufacturing facilities throughout the world. For more information, visit http://www.Integra-LS.com.
Founded in 1998, Irving, Texas-based, Novation is the leading health care contracting services company, delivering savings and value to nearly 2,500 members of VHA Inc. and the University HealthSystem Consortium (UHC), two national health care alliances, and nearly 12,000 members of Provista, LLC. Through its competitive contracting process, Novation develops and manages contracts with more than 500 suppliers. Novation offers an extensive range of advanced contracting services, including: contract development, contract and supplier management, custom contracting, enhanced savings programs, online contract management and analytical tools, order management and online supplier connectivity. VHA, UHC and Provista members used Novation contracts to purchase more than $33.1 billion in 2007. For more information about Novation, visit http://www.novationco.com/
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use Integra products may affect the prospects for their use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading ``Risk Factors'' included in section IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2007 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
Source: Integra LifeSciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.